دورية أكاديمية
Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.
| العنوان: | Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. |
|---|---|
| المؤلفون: | Olmeda D; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Cerezo-Wallis D; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Riveiro-Falkenbach E; Department of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain., Pennacchi PC; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Contreras-Alcalde M; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Ibarz N; Proteomics Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Cifdaloz M; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Catena X; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Calvo TG; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Cañón E; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Alonso-Curbelo D; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Suarez J; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Osterloh L; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Graña O; Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Mulero F; Molecular Imaging Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Megías D; Confocal Microscopy Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Cañamero M; Histopathology Unit, Biotechnology Programme,Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Martínez-Torrecuadrada JL; Crystallography and Protein Engineering Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Mondal C; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Di Martino J; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Lora D; CIBERESP, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain., Martinez-Corral I; Transgenic Mice Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Bravo-Cordero JJ; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Muñoz J; Proteomics Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Puig S; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques d'August Pi i Sunyer, 08036 Barcelona, Spain., Ortiz-Romero P; Department of Dermatology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain., Rodriguez-Peralto JL; Department of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain., Ortega S; Transgenic Mice Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain., Soengas MS; Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. |
| المصدر: | Nature [Nature] 2017 Jun 28; Vol. 546 (7660), pp. 676-680. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Basingstoke : Nature Publishing Group Original Publication: London, Macmillan Journals ltd. |
| مواضيع طبية MeSH: | Cytokines/*metabolism , Lymphatic Vessels/*metabolism , Neoplasm Metastasis/*diagnostic imaging , Neoplasm Metastasis/*pathology , Whole Body Imaging/*methods, Animals ; Disease Models, Animal ; Disease Progression ; Endothelial Cells/metabolism ; Female ; Genes, Reporter ; Humans ; Lymphangiogenesis ; Lymphatic Vessels/pathology ; Male ; Melanoma/diagnostic imaging ; Melanoma/metabolism ; Melanoma/pathology ; Mice ; Midkine ; Paracrine Communication ; Prognosis ; Recurrence ; Reproducibility of Results ; TOR Serine-Threonine Kinases/metabolism ; Vascular Endothelial Growth Factor Receptor-3/analysis ; Vascular Endothelial Growth Factor Receptor-3/metabolism ; Xenograft Model Antitumor Assays |
| مستخلص: | Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis. However, sentinel lymph node removal does not necessarily extend the overall survival of patients with melanoma. Moreover, lymphatic vessels collapse and become dysfunctional as melanomas progress. Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis. Soluble and vesicle-associated proteins secreted by tumours and/or their stroma have been proposed to condition pre-metastatic sites in patients with melanoma. Still, the identities and prognostic value of lymphangiogenic mediators remain unclear. Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic niches. Injectable lymphatic tracers have been developed, but their limited diffusion precludes whole-body imaging at visceral sites. Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive 'lymphoreporter' because its expression is strongly downregulated in normal adult lymphatic endothelial cells, but is activated in pathological situations such as inflammation and cancer. Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a 'MetAlert' discovery platform for drivers and inhibitors of metastasis. |
| التعليقات: | Comment in: Nature. 2017 Jun 28;546(7660):609-610. (PMID: 28658216) Comment in: Pigment Cell Melanoma Res. 2017 Jan;30(6):509-510. (PMID: 28756632) Comment in: Dev Cell. 2017 Aug 7;42(3):205-207. (PMID: 28787586) |
| References: | Cancer Res. 2011 Nov 15;71(22):7103-12. (PMID: 21975930) Cancer Cell. 2008 Jun;13(6):554-6. (PMID: 18538738) J Biochem. 2013 Jun;153(6):511-21. (PMID: 23625998) Nat Rev Cancer. 2014 Mar;14(3):159-72. (PMID: 24561443) Am J Cancer Res. 2015 Aug 15;5(9):2912-7. (PMID: 26609495) Mol Oncol. 2013 Apr;7(2):259-82. (PMID: 23522958) Nature. 2005 Dec 8;438(7069):820-7. (PMID: 16341007) Cancers (Basel). 2010 Apr 20;2(2):624-41. (PMID: 24281085) Biomaterials. 2013 Jul;34(21):5128-37. (PMID: 23566803) Neoplasia. 2012 Mar;14(3):228-37. (PMID: 22496622) Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6223-8. (PMID: 22474390) Br J Pharmacol. 2014 Feb;171(4):811-3. (PMID: 24460672) J Cell Biochem. 2016 Jul;117(7):1697-706. (PMID: 26666522) J Exp Med. 2013 Jul 29;210(8):1509-28. (PMID: 23878309) J Clin Invest. 2014 Mar;124(3):922-8. (PMID: 24590277) Science. 2002 Jun 7;296(5574):1883-6. (PMID: 11976409) Genome Biol. 2009;10(3):R25. (PMID: 19261174) Cancer Res. 1997 May 1;57(9):1814-9. (PMID: 9135027) Genesis. 2006 Jan;44(1):34-43. (PMID: 16419042) Intravital. 2013 Apr 1;2(2):e25294. (PMID: 25013744) Nat Protoc. 2012 Mar 01;7(3):562-78. (PMID: 22383036) Br J Pharmacol. 2014 Jun;171(12):2925-39. (PMID: 24460734) J Clin Invest. 2014 Mar;124(3):878-87. (PMID: 24590272) Nature. 2015 Nov 19;527(7578):329-35. (PMID: 26524530) Cancer Cell. 2016 Nov 14;30(5):668-681. (PMID: 27846389) Front Oncol. 2016 Nov 15;6:240. (PMID: 27896217) Am J Physiol Heart Circ Physiol. 2012 Aug 15;303(4):H429-38. (PMID: 22707563) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Br J Cancer. 2010 May 25;102(11):1555-77. (PMID: 20502460) Nat Cell Biol. 2006 Oct;8(10):1053-63. (PMID: 16964246) Nature. 2015 Apr 16;520(7547):368-72. (PMID: 25807485) N Engl J Med. 2014 Feb 13;370(7):599-609. (PMID: 24521106) Nat Rev Clin Oncol. 2014 May;11(5):248-9. (PMID: 24710577) Nat Methods. 2009 May;6(5):359-62. (PMID: 19377485) Br J Pharmacol. 2014 Feb;171(4):896-904. (PMID: 24116381) Nat Med. 2012 Jun;18(6):883-91. (PMID: 22635005) Toxicol Pathol. 2006;34(5):409-24. (PMID: 17067937) Nature. 2001 Jan 11;409(6817):207-11. (PMID: 11196646) Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943) J Clin Invest. 2014 Mar;124(3):905-14. (PMID: 24590275) Science. 2016 Apr 8;352(6282):242-6. (PMID: 26989197) Development. 2002 Jul;129(14):3513-22. (PMID: 12091320) Nat Genet. 2009 May;41(5):544-52. (PMID: 19282848) |
| معلومات مُعتمدة: | 15-1374 United Kingdom AICR_ Worldwide Cancer Research; K22 CA196750 United States CA NCI NIH HHS; P30 CA196521 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Cytokines) 137497-38-2 (Midkine) EC 2.7.10.1 (FLT4 protein, human) EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-3) EC 2.7.11.1 (TOR Serine-Threonine Kinases) |
| تواريخ الأحداث: | Date Created: 20170629 Date Completed: 20171023 Latest Revision: 20220129 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6005659 |
| DOI: | 10.1038/nature22977 |
| PMID: | 28658220 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-4687 |
|---|---|
| DOI: | 10.1038/nature22977 |